The Medical Advisor

Abstract Immune checkpoint pathways such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) play a central role in regulating immune activation, tolerance, and exhaustion. While pharmaceutical checkpoint inhibitors have transformed cancer treatment, there is growing interest in whether lifestyle factors and dietary supplements can modulate these pathways indirectly. This article reviews the biological plausibility, preclinical evidence, and limitations surrounding non-pharmacologic modulation of PD-1 and CTLA-4 signaling, emphasizing immune tone optimization rather than immune checkpoint blockade. Keywords: PD-1, CTLA-4, immune checkpoints, immune exhaustion, lifestyle medicine, supplements, immunometabolism Scope and Intent This article is educational and mechanistic , not therapeutic guidance. It does not suggest lifestyle or supplements can replace immune checkpoint inhibitors. It does not advocate off-label cancer treatment. It examines in...

Cancer immunotherapy (CIT) has become a standard of care in multiple indications. Apart from radically increasing response rate and prolonging survival, CIT offers the ultimate benefit of any therapy, which is a cure (1). Credit: Statista Since the early days of CIT, it was recognized that the benefit is driven by complicated biological mechanisms, which involves a cross-talk between the tumor, its microenvironment, and the overall immune system of the patient ( 2 ,  3 ). Studies aiming to understand and explore CIT mechanisms of action and pharmacodynamic and response prediction biomarkers have initially evaluated each component independently, but ultimately need to look at these questions in concert. Technological advancements in the field combined with the availability of better translational models and ever-expanding clinical datasets enabled basic, translational, and clinical researchers to have a deeper understanding of this complex interaction ( 4 – 8 ). This combined Resear...

In the ever-evolving field of oncology, understanding genetics and genomics is crucial for patients, families, and healthcare providers alike. Genetics focuses on the study of genes and their role in inheritance—how certain traits or conditions are passed from one generation to the next. Genetic testing identifies inherited mutations present in every cell of the body since birth (known as germline testing). This can be performed via a blood test, cheek swab, or saliva sample. In cancer care, it's vital because it detects inherited predispositions to specific cancers, such as those linked to BRCA1/2, ATM, PALB2, CHEK2, BRIP1, Lynch syndrome, and others. These insights inform treatment choices, surveillance strategies, risk-reduction measures, and family testing recommendations. Genomics, on the other hand, examines a person's entire genome. In cancer, genomic testing analyzes the tumor cells to pinpoint gene or protein alterations that distinguish them from healthy cells. By se...